Changeflow GovPing Pharma & Drug Safety Aqueous Gel Composition for Administering Activ...
Routine Notice Added Final

Aqueous Gel Composition for Administering Active Agents

Email

Summary

The USPTO has published a new patent application, US20260083669A1, filed by Acousia Therapeutics GmbH. The application describes an aqueous gel composition useful for administering pharmaceutically active agents, particularly for transtympanic administration.

What changed

This document is a newly published patent application from the USPTO, specifically application US20260083669A1, filed by Acousia Therapeutics GmbH. The application details an aqueous gel composition designed for the administration of active pharmaceutical agents, with a particular focus on transtympanic delivery. Key components include specific percentages of surfactants, an alcohol, and water.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it is relevant for pharmaceutical companies and researchers in the drug delivery space, particularly those involved in otic formulations. Companies should be aware of this and similar patent filings as they relate to their own intellectual property strategies and product development pipelines.

Source document (simplified)

← USPTO Patent Applications

AQUEOUS GEL COMPOSITION

Application US20260083669A1 Kind: A1 Mar 26, 2026

Assignee

Acousia Therapeutics GmbH

Inventors

Sven Heymans, Peter Jan Robert Kool, Julia Eva Diederichs, Jonas Dyhrfjeld-Johnsen

Abstract

The present invention discloses an aqueous gel composition which is useful for administration of pharmaceutically active agents, in particular for transtympanic administration of pharmaceutically active agents. The aqueous gel composition comprises
at least one first surfactant in an amount from 10% to 30% by weight, based on the total weight of the composition,at least one second surfactant in an amount from 5% to 20% by weight, based on the total weight of the composition,at least one alcohol in an amount from 5% to 20% by weight, based on the total weight of the composition,and water in an amount of at least 30% by weight, based on the total weight of the composition.

CPC Classifications

A61K 9/06 A61K 31/381 A61K 47/10 A61K 47/24

Filing Date

2023-05-17

Application No.

18695511

View original document →

Named provisions

Abstract

Classification

Agency
USPTO
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083669A1

Who this affects

Applies to
Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Drug Formulation Drug Delivery
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Drug Delivery Intellectual Property

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Pharma (A61K) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.